右美托咪啶在临床麻醉中应用的研究进展被引量：483

Advance in search for clinical use of dexmedetomidine in anesthesiology

下载PDF

导出

摘要右美托咪啶为新型高选择性α2肾上腺素能受体激动剂,它具有剂量依赖性的镇静催眠作用,还具有镇痛、抑制交感活性、无呼吸抑制等药理性质。1999年美国FDA批准将其用于重症监护病房的镇静。在围术期"规定范围之外"的应用表明,右美托咪啶还具有稳定血流动力学、抑制应激反应、减少麻醉剂及阿片类药物的用量和抗寒颤等作用。本文对右美托咪啶的药理学性质以及围术期临床应用进展进行介绍。 Dexmedetomidine is a novel and highly selective a2-adrenoceptor agonist. Dexmedetomidine offers beneficial pharmacological properties, providing dose-dependent sedation, analgesia, sympatholysis and without relevant respiratory depression. Dexmedetomidine was approved for sedation in the intensive care unit in the USA in 1999. The ‘off-label’ use of dexmedetomidine during the perioperative period has proved that it can attenuate hemodynamic responses to anesthesia and surgery, decrease sympathetic tone, reduce anesthetic and opioid requirements and prevent postanesthetic shivering. This review aims to present and discuss the pharmacological properties and perioperative use of dexmedetomidine.

作者李民张利萍吴新民

机构地区北京大学第三医院麻醉科北京大学第一医院麻醉科

出处《中国临床药理学杂志》 CAS CSCD 北大核心 2007年第6期466-470,共5页 The Chinese Journal of Clinical Pharmacology

关键词右美托咪啶 Α2肾上腺素能受体麻醉重症监护 dexmedetomidine α2-adrenoceptors anesthesia intensive care

分类号 R971.3 [医药卫生—药品] R972.4 [医药卫生—药品]

引文网络
相关文献

参考文献39

1[1]Khan ZP,Ferguson CN,Jones RM.Alpha-2 and imidazoline receptor agonists:their pharmacology and therapeutic role[J].Anesthesia,1999;54:146-165.
2[2]Kamibayashi T,Maze M.Clinical uses of alpha 2-adrenergic agonists[J].Anesthesiology,2000;93:1345-1350.
3[3]Calzada BC,De Artinano AA.[alpha]2-Adrenoreceptor subtypes[J].Pharmacol Res,2001;44:195-208.
4[4]Hunter JC,Fontanna DJ,Hedley LR,et al.Assessment of the role of alpha 2-adrenoceptor subtypes in the antinociceptive,sedative and hypothermic action of dexmedetomidine in transgenic mice[J].Br J Pharmacol,1997;122:1339-1344.
5[5]Nelson LE,Lu J,Guo TZ,et al.The α2-Adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects[J].Anesthesiology,2003;98:428-436.
6[6]Coull JT,Jones M,Egan T,et al.Attentionla effects of noradranaline vary with arousal level:selective activation of thalamie pulvinar in humans[J].Neuro Image,2004;22:315-322.
7[7]Eisenach JC.[Alpha]2 agonists and analgesia[J].Exp Opin Invest Drugs,1994;3:1005-1010.
8[8]Ma D,Rajakumamswamy N,Maze M.Alpha2-Adrenoceptor agonists:shedding light on neuroprotection?[J].Br Med Bull,2005;71:77-92.
9[9]Ebert TJ,Hall JE,Barney JA,et al.The effects of increasing plasma concentrations of dexmedetomidine in humans[J].Anesthesiology,2000;93:382-394.
10[10]Ramsey MA,Luterman DL.Dexmedetomidine as a total intravenous anesthestic agent[J].Anesthesiology,2004;101:787-781.